Dewpoint’s new drug candidate targets ALS protein clumps
Dewpoint Therapeutics has selected a novel small molecule designed to prevent the formation of abnormal TDP-43 protein clumps that…
Articles by Andrea Lobo, PhD
New TDP-43-targeting antibodies may open a path for ALS treatment
Mindwalk Holdings has identified and validated antibodies that selectively target an abnormal form of the TDP-43 protein, which is…
1st patient dosed in Phase 2 trial of SOD1-ALS treatment RAG-17
The first patient has been dosed in a Phase 2 clinical study testing RAG-17, a therapy being developed by…
First human trial begins in Europe for ALS, Parkinson’s drug NRG5051
The first participants have been dosed in an early Phase 1 clinical study that’s testing NRG5051, a first-in-class treatment…
Device for slowing ALS progression wins FDA breakthrough status
An experimental, noninvasive device for slowing the progression of functional symptoms in people with amyotrophic lateral sclerosis (ALS) has…
Foralumab nasal spray joins pathway to HEALEY platform trial
A Phase 2 clinical trial to investigate Tiziana Life Sciences’ intranasal foralumab for the treatment of amyotrophic lateral…
Aperture to advance potential treatment for ALS and dementia
Aperture Therapeutics has selected APRTX-001 as its lead candidate to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative…
Scientists to study how abnormal protein drives ALS
The Robert Packard Center for ALS Research at Johns Hopkins and ALS United will fund a preclinical study investigating how…
New interactive tool provides free access to real-world ALS data
The ALS Association has launched the ALS Focus Data Dashboard, a free interactive tool that gives researchers, clinicians, and…
Insitro, Bristol Myers extend research into new drug for ALS
Bristol Myers Squibb is extending a research collaboration with the artificial intelligence company Insitro to design new medicines…